Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Research at the Kennedy Institute reveals sub-populations of stromal cells with distinct functions in human fibrotic disease. These findings could inform development of more specific therapies with fewer off-target effects.

Dupuytren’s disease hand examination.
The study used human fibrotic tissue from Dupuytren’s disease, a common fibrotic condition of the hand

In their study, published in Nature Communications, the authors utilised single cell technologies to map different types of stromal cells and their relationship to each other in human tissues affected by fibrosis. Their approach revealed several distinct populations of stromal cells with different functional roles.

Fibrotic disorders arise from poorly regulated tissue repair processes, leading to a build-up of collagen and scar tissue that impairs organ function. These diseases are some of the most devastating and poorly treated conditions in the Western world, yet effective therapeutics are often lacking. 

Lead author Jagdeep Nanchahal said: "Animal models fail to replicate many aspects of human fibrosis and there remains limited availability of well-characterised patient samples at developing stages of disease. Our study exclusively used human fibrotic tissue from Dupuytren's disease, a common fibrotic condition of the hand, to profile an entire human fibrotic ecosystem at single cell resolution."


"We were able to build a single cell atlas of human fibrosis-promoting stromal cells and describe functionally distinct types and states. This division of labour between fibrotic stromal cells will allow us to form a powerful translational resource to help inform development of treatments and represents an exciting avenue for future research," he concluded.

Similar stories

Could patients with common fractures recover without routine hospital follow-up?

The FASTER study will investigate whether thousands of people with common fractures can recover just as well with good-quality advice and rehabilitation guidance, without the need for routine hospital follow-up appointments.

Could the gut’s nervous system hold new clues to treating Crohn’s disease?

Researchers at the Kennedy Institute are investigating whether the nervous system within the gut could provide a new way to understand and ultimately treat Crohn’s disease.

NDORMS appoints a new Research Professor of Regulatory Innovation to help accelerate the development pipeline of new treatments

Lincoln Tsang has been appointed as the new John Climax Research Professor of Regulatory Innovation – a new role at NDORMS and the University of Oxford that brings global regulatory and legal expertise to our ambitions to transform and improve drug development pathways in order to help deliver safe and effective treatments to patients sooner. He will assume this role effective 2 January 2027.

Look Beyond My Skin: Your Psoriasis Could Help Us Understand Who Develops Psoriatic Arthritis

Adults with psoriasis across Europe are invited to take part in an online study aiming to identify who is at risk of developing psoriatic arthritis.

New PI Marie Pust aims to bring microbiome research closer to patients

We welcome Marie-Madlen Pust, who has joined the Kennedy Institute as a new Principal Investigator. Marie will establish a research group combining computational biology with targeted experimental microbiology to identify microbial drivers of chronic inflammatory disease that can be monitored (diagnostic potential) or modified (therapeutic potential).

Oxford EMCRF starts pioneering engineered nTreg trial for severe autoimmune disease

The Oxford Experimental Medicine Clinical Research Facility (EMCRF) has recruited its first patients into the CHILL trial, an early-phase study of an innovative cell therapy for severe autoimmune disease.